SFX by Ex Libris Inc.

Title:	A Mutation in CFTR Modifies the Effects of the Adenylate Kinase Inhibitor Ap5A on Channel Gating
Source:	Biophysical Journal [0006-3495] Dong, Qian yr:2008

Basic

Full text

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Wang, X. "Mutations at the signature sequence of CFTR create a Cd(2+)-gated chloride channel." The journal of general physiology 133.1 (2009): 69-77.
description	2.	SD, D. "Hitting the target: new treatments for cystic fibrosis." American journal of respiratory and critical care medicine 182.12 (2010): 1460-1.
description	3.	Zhang, L. "CFTR Delivery to 25% of Surface Epithelial Cells Restores Normal Rates of Mucus Transport to Human Cystic Fibrosis Airway Epithelium." PLoS biology 7.7 (2009): 1-1.
description	4.	Hegedus, T. "Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A." Biochimica et biophysica acta. Biomembranes 1788.6 (2009): 1341-1349.
description	5.	Amaral, M. "Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis." Trends in Pharmacological Sciences 28.7 (2007): 334-341.
description	6.	Cheng, S H H. "Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis." Cell 63.4 (1990): 827-34.
description	7.	Ellgaard, L. "Quality control in the endoplasmic reticulum." Nature reviews. Molecular cell biology 4.3 (2003): 181-191.
description	8.	Powell, K. "Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting." Advanced Drug Delivery Reviews 54.11 (2003): 1395-408.
description	9.	Lukacs, Gergely L. "CFTR: folding, misfolding and correcting the ΔF508 conformational defect." Trends in molecular medicine 18.2 (2011): 81-91.
description	10.	Dellon, Elisabeth P. "Family Caregiver Perspectives on Symptoms and Treatments for Patients Dying From Complications of Cystic Fibrosis." Journal of pain and symptom management 40.6 (2010): 829-837.
description	11.	Stanton, Bruce A. "New insights into cystic fibrosis: molecular switches that regulate CFTR." Nature reviews. Molecular cell biology 7.6 (2006): 426-36.
description	12.	Welsh, Michael J. "Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis." Cell 73.7 (1993): 1251-4.
description	13.	Rogan, Mark P. "Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific Treatment." Chest 139.6 (2011): 1480-1490.
description	14.	Dolgin, E. "Mutation-specific cystic fibrosis treatments on verge of approval." Nature medicine 17.4 (2011): 396-397.
description	15.	Collaco, Garry M. "Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes." American journal of respiratory and critical care medicine 182.9 (2010): 1137-1143.
description	16.	Jones, Andrew M. "Emerging treatments in cystic fibrosis." Drugs 69.14 (2009): 1903-10.
description	17.	Van Goor, F. "Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules." American journal of physiology. Lung cellular and molecular physiology 290.6 (2006): 1117-30.
description	18.	Cuthbert, Alan W W. "The prospects of pharmacotherapy for cystic fibrosis." Journal of the Royal Society of Medicine 99.46 (2006): 30-5.
description	19.	Lewis, Hal A. "Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator." The EMBO journal 23.2 (2004): 282-293.
description	20.	Riederer, S. "Knockout mouse models for intestinal electrolyte transporters and regulatory PDZ adaptors: new insights into cystic fibrosis, secretory diarrhoea and fructose-induced hypertension." Experimental physiology 94.2 (2009): 175-9.